Status:
RECRUITING
The Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer Patients
Lead Sponsor:
Peking University People's Hospital
Conditions:
Lung Cancer
Postoperative Pain
Eligibility:
All Genders
18-80 years
Brief Summary
The concentration of plasma programmed death-ligand 1(PD-L1) for lung cancer patients before video-assisted thoracoscopic surgery is detected. According to the distribution of plasma concentration, pa...
Detailed Description
Chronic pain after video-assisted thoracoscopic surgery (VATS) has been a major concern for lung cancer patients. The relationship between plasma programmed cell death ligand-1 (PD-L1) concentration a...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists physical status I-IV (males and females).
- 18-80 years of age.
- Patients undergoing video-assisted thoracoscopic surgery for malignant lung disease.
Exclusion
- History of opioid abuse.
- Known psychiatric disorders.
- Unexpected conversion to thoracotomy or transferred to intensive care unit for further treatment.
- Combined with other surgeries or sites.
Key Trial Info
Start Date :
July 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06503432
Start Date
July 20 2024
End Date
March 1 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100037